Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06055179

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Led by Guangzhou University of Traditional Chinese Medicine · Updated on 2025-07-01

98

Participants Needed

1

Research Sites

142 weeks

Total Duration

On this page

Sponsors

G

Guangzhou University of Traditional Chinese Medicine

Lead Sponsor

U

University of Houston

Collaborating Sponsor

AI-Summary

What this Trial Is About

Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.

CONDITIONS

Official Title

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Malignant tumor confirmed by histology or cytology
  • Age 18 years or older and 75 years or younger
  • ECOG performance score of 2 points or less
  • Experienced diarrhea worse than grade 2 due to irinotecan chemotherapy within the last month
  • Planning to receive at least 3 cycles of irinotecan chemotherapy with dose 125 mg/m2 or higher
  • Normal bone marrow function: neutrophil count ≥ 1.5×10⁹/L, platelets ≥ 100×10⁹/L, hemoglobin ≥ 90 g/L
  • Normal kidney function: serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min
  • Normal liver function: total bilirubin ≤ 1.5 times upper normal limit, AST and ALT ≤ 2.5 times upper normal limit; if abnormal due to tumor, AST and ALT ≤ 5 times upper normal limit
  • Able to understand and complete questionnaires
  • Able to understand and sign informed consent and comply with study procedures
Not Eligible

You will not qualify if you...

  • Diagnosis of depression, obsession, or schizophrenia
  • Diagnosis of inflammatory bowel diseases such as Crohn's disease or ulcerative colitis
  • Active tuberculosis or other uncontrolled infections
  • Previous radiotherapy to abdominal or pelvic area
  • Pregnant or breastfeeding women
  • History or current thromboembolic events

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Guangdong Provincial Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, China, 510120

Actively Recruiting

Loading map...

Research Team

Y

Yanjuan Zhu, Dr.

CONTACT

Y

Yadong Chen, Dr.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here